ArticleBreast cancer research : BCR2012
Back to the embryonic stage: Nodal as a biomarker for breast cancer progression.
Article in Breast cancer research : BCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells.Disease models & mechanisms · 2021Article
- Pubertal high fat diet: effects on mammary cancer development.Breast cancer research : BCR · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The embryonic morphogen Nodal, a member of the transforming growth factor-β superfamily, is not expressed in the majority of normal adult tissues. However, a growing body of evidence indicates that Nodal expression re-emerges in a number of human cancers, including melanoma, glioma, endometrial, and prostate cancers. Reactivation of Nodal signaling in these tumors contributes to their aggressiveness. Strizzi and colleagues, in a paper published in this issue of Breast Cancer Research, investigate the clinical significance of Nodal expression in breast cancer. They report that Nodal expression is significantly greater in malignant versus benign breast disease. More importantly, Nodal levels correlated with grading, staging, and lymph node involvement, independent of the estrogen receptor/progesterone receptor or HER2 status. Collectively, these data suggest that Nodal could serve as a potential biomarker for invasive disease and a potential therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.